Connect with us

Hot Penny Stocks To Watch Before Today’s Opening Bell

These penny stocks are on the move, early and here’s why.
The post Hot Penny Stocks To Watch Before Today’s Opening Bell appeared first on Penny Stocks to Buy, Picks, News and Information |



As they say, the early bird gets the worm, and there are no worms quite like penny stocks. Thanks to even the slightest catalyst, these cheap shares can spike hundreds of percentage points within a single day. While not all penny stocks trade during premarket hours, you’re sure to find at least a few making waves early. The thing to remember about premarket momentum is that it is much different than the regular session.

Many traders don’t have accessibility to premarket trading, so volumes are lower. It is an exciting session during the full market hours and something to keep in mind if you’re looking to identify potential follow-through trends heading into the first have of the day.

Penny Stocks TL;DR 30-Second Summary

  • Pre-market trading is a time where some of the biggest moves are made for some penny stocks
  • Not all traders have access or the ability to trade before the 9:30AM ET
  • If you are able to trade pre-market, it may be wise to treat it like a different sessions entirely
  • Despite the risk, pre-market trends can sometimes give an indication for what’s to come during the normal session
  • Today we look at a few of the hot penny stocks to watch before the opening bell. The question to answer now is will there be enough followthrough during the normal session to see momentum continue?

Despite some of the shortcomings if you cannot trade penny stocks during pre-market hours, there are cues to take into account. The most frequently used signal is trading volume and directional momentum. How’s the stock performing heading into the open, and can you trust the trend? Believe it or not, even some of the hottest stocks to watch pre-market can fade as soon as the bell rings. If you’re on the hunt for new stocks to buy based on early trends, keep this in mind.

Penny Stocks To Watch Pre-Market

American Virtual Cloud Technologies, Inc. (NASDAQ: AVCT)

Ever since early December, American Virtual has been on the rebound path. So far, AVCT stock has managed to jump from lows of $0.84 to highs of more than $2.60 during pre-market trading on December 29th. The company provides IT solutions for its clients ranging from cybersecurity to enhanced connectivity & cloud communications. The most significant point of focus lately, however, has been on the company’s Kandy Communications Business.

Why Is AVCT Stock Moving?

American Virtual came out late Tuesday afternoon with news after the closing bell. Kandy Communications announced the growth of its partnership with Etisalat, a telecom group in emerging markets. It also reported new offerings that will allow for embedded communications in business applications for large enterprises in those markets.

Read: Best Reddit Penny Stocks to Buy Now? 3 You Need to Watch in 2022

The new offerings include embedding real-time communications into critical telehealth applications. According to the company, Etisalat has enabled leading UAE hospitals to offer access to on-demand healthcare to improve medical outcomes.

MingZhu Logistics Holdings Ltd.(NASDAQ: YGMZ)

As you’ll see on the YGMZ stock chart, things have been volatile over the last few weeks. However, something else to note is that since reaching its 52-week low this month, MingZhu has managed to bounce back much more robust than compared to earlier this year. As with many penny stocks, YGMZ is experiencing a Santa Claus rally of its own, and that continued after new developments emerged this week for the Chinese trucking company.

Why Is YGMZ Stock Moving?

Wednesday morning MingZhu announced a new share purchase agreement to buy out Cheyi Limited. Cheyi operates an online ride-hailing and driver management service company. The nearly $30 million acquisition will see MingZhu bring on a company that hosts more than 6,000 vehicles and drivers for ride-hailing services.

CEO, Jinlong Yang explained, “This immediately broadens our portfolio and will serve as a centerpiece of our continued diversification strategy. Our priority remains unchanged. We are focused on accelerating our growth strategy by strategically deploying capital in both organic and inorganic opportunities, as we unlock MingZhu’s potential and greater value for shareholders.”

premarket movers penny stocks to watchMingZhu Logistics Holdings YGMZ stock chart

Can-Fite BioPharma Ltd. (NYSE: CANF)

We discussed Can-Fite earlier this month in our article “5 Penny Stocks To Buy For Under $5 This Week” and highlighted Can-Fite’s Phase IIb study of its NASH drug candidate Namodenoson. Following clearance from the Israeli Ministry of Health, the company expects to begin the next portion in studying Namodenoson. A prior Phase IIa clinical trial of Namodenoson in the treatment of NASH met study endpoints showing anti-steatotic, anti-inflammatory, and anti-fibrotic effects. in Q4 2021.

Read: 3 Top Penny Stocks To Buy For Under $1 This Week

A day after our update, the company announced its Open Label Extension program of its concluded Phase II study of Namodenoson experienced a Complete Response (CR) to Can-Fite’s drug. That means that all cancer lesions have cleared according to the company. Things have been volatile ever since and CANF stock has traded in a very wide range.

Why Is CANF Stock Moving?

Once again CANF stock is in ews headlines. This week the company announced that it is filing new patent applications in several countries for the treatment of all advanced solid tumors. This was based on the recent clinical data from the Complete Response receipt. Can-Fite said that “These pending patent applications are the latest in Can-Fite’s growing IP portfolio covering its platform technology, as well as its drug candidate Namodenoson and its use in a variety of advanced cancers.”

Looking ahead, Can-Fite said that it expects to begin enrollment in a Phase III trial for Namodenoson in patients with advanced HCC with underlying Child Pugh B7 (CPB7) cirrhosis. This will be used to support a New Drug Application submission and hopeful approval.

premarket movers penny stocks to watch Can Fite BioPharma Ltd. CANF stock chart

NRx Pharmaceuticals (NASDAQ: NRXP)

Shares of NRx Pharmacetucals shot higher during pre-market trading on December 29th. The biotech company has recently placed its focus on small molecule drugs for inflammation. With the virus pandemic placing a lot of attention on related companies either making a drug, a test, or something else, there’s no shortage of speculative momentum in the biotech space.

Why Is NRXP Stock Moving?

While NRx has a robust pipeline of multiple candidates, this morning news regarding its ZYESAMI platform. Specifically, it filed filed a new Breakthrough Therapy Designation request with the FDA. The focus is on patients with Critical COVID-19 and respiratory failure “who are at immediate risk of death despite treatment with remdesivir and other approved therapies.”

“At a time when America is entering a new COVID-related crisis, we thank the FDA for encouraging us to address the subset of patients who have no other approved treatment…More than 2,000 Americans died from COVID-19 on Christmas eve . With the FDA’s support, we believe we have the chance to help more than 100,000 Americans return to their loved ones who otherwise might not live to see next year’s holidays.”

Prof Jonathan Javitt , MD, MPH, Chairman and CEO of NRx Pharmaceuticals

With a focus on vaccines and alternative treatments, NRXP has turned some heads with this news.

premarket movers penny stocks to watch NRx Pharmaceuticals NRXP stock chart

Premarket Movers

When it comes to premarket movers, there are plenty of things to account for. In particular, paying attention to these premarket trends is key in determining to strength of the move. In many cases, stocks fade after the opening bell so keep a close eye on trading volume as the regular session begins.

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!

The post Hot Penny Stocks To Watch Before Today’s Opening Bell appeared first on Penny Stocks to Buy, Picks, News and Information |

Read More

Continue Reading


Homes listed for sale in early June sell for $7,700 more

New Zillow research suggests the spring home shopping season may see a second wave this summer if mortgage rates fall
The post Homes listed for sale in…



  • A Zillow analysis of 2023 home sales finds homes listed in the first two weeks of June sold for 2.3% more. 
  • The best time to list a home for sale is a month later than it was in 2019, likely driven by mortgage rates.
  • The best time to list can be as early as the second half of February in San Francisco, and as late as the first half of July in New York and Philadelphia. 

Spring home sellers looking to maximize their sale price may want to wait it out and list their home for sale in the first half of June. A new Zillow® analysis of 2023 sales found that homes listed in the first two weeks of June sold for 2.3% more, a $7,700 boost on a typical U.S. home.  

The best time to list consistently had been early May in the years leading up to the pandemic. The shift to June suggests mortgage rates are strongly influencing demand on top of the usual seasonality that brings buyers to the market in the spring. This home-shopping season is poised to follow a similar pattern as that in 2023, with the potential for a second wave if the Federal Reserve lowers interest rates midyear or later. 

The 2.3% sale price premium registered last June followed the first spring in more than 15 years with mortgage rates over 6% on a 30-year fixed-rate loan. The high rates put home buyers on the back foot, and as rates continued upward through May, they were still reassessing and less likely to bid boldly. In June, however, rates pulled back a little from 6.79% to 6.67%, which likely presented an opportunity for determined buyers heading into summer. More buyers understood their market position and could afford to transact, boosting competition and sale prices.

The old logic was that sellers could earn a premium by listing in late spring, when search activity hit its peak. Now, with persistently low inventory, mortgage rate fluctuations make their own seasonality. First-time home buyers who are on the edge of qualifying for a home loan may dip in and out of the market, depending on what’s happening with rates. It is almost certain the Federal Reserve will push back any interest-rate cuts to mid-2024 at the earliest. If mortgage rates follow, that could bring another surge of buyers later this year.

Mortgage rates have been impacting affordability and sale prices since they began rising rapidly two years ago. In 2022, sellers nationwide saw the highest sale premium when they listed their home in late March, right before rates barreled past 5% and continued climbing. 

Zillow’s research finds the best time to list can vary widely by metropolitan area. In 2023, it was as early as the second half of February in San Francisco, and as late as the first half of July in New York. Thirty of the top 35 largest metro areas saw for-sale listings command the highest sale prices between May and early July last year. 

Zillow also found a wide range in the sale price premiums associated with homes listed during those peak periods. At the hottest time of the year in San Jose, homes sold for 5.5% more, a $88,000 boost on a typical home. Meanwhile, homes in San Antonio sold for 1.9% more during that same time period.  


Metropolitan Area Best Time to List Price Premium Dollar Boost
United States First half of June 2.3% $7,700
New York, NY First half of July 2.4% $15,500
Los Angeles, CA First half of May 4.1% $39,300
Chicago, IL First half of June 2.8% $8,800
Dallas, TX First half of June 2.5% $9,200
Houston, TX Second half of April 2.0% $6,200
Washington, DC Second half of June 2.2% $12,700
Philadelphia, PA First half of July 2.4% $8,200
Miami, FL First half of June 2.3% $12,900
Atlanta, GA Second half of June 2.3% $8,700
Boston, MA Second half of May 3.5% $23,600
Phoenix, AZ First half of June 3.2% $14,700
San Francisco, CA Second half of February 4.2% $50,300
Riverside, CA First half of May 2.7% $15,600
Detroit, MI First half of July 3.3% $7,900
Seattle, WA First half of June 4.3% $31,500
Minneapolis, MN Second half of May 3.7% $13,400
San Diego, CA Second half of April 3.1% $29,600
Tampa, FL Second half of June 2.1% $8,000
Denver, CO Second half of May 2.9% $16,900
Baltimore, MD First half of July 2.2% $8,200
St. Louis, MO First half of June 2.9% $7,000
Orlando, FL First half of June 2.2% $8,700
Charlotte, NC Second half of May 3.0% $11,000
San Antonio, TX First half of June 1.9% $5,400
Portland, OR Second half of April 2.6% $14,300
Sacramento, CA First half of June 3.2% $17,900
Pittsburgh, PA Second half of June 2.3% $4,700
Cincinnati, OH Second half of April 2.7% $7,500
Austin, TX Second half of May 2.8% $12,600
Las Vegas, NV First half of June 3.4% $14,600
Kansas City, MO Second half of May 2.5% $7,300
Columbus, OH Second half of June 3.3% $10,400
Indianapolis, IN First half of July 3.0% $8,100
Cleveland, OH First half of July  3.4% $7,400
San Jose, CA First half of June 5.5% $88,400


The post Homes listed for sale in early June sell for $7,700 more appeared first on Zillow Research.

Read More

Continue Reading


Survey Shows Declining Concerns Among Americans About COVID-19

Survey Shows Declining Concerns Among Americans About COVID-19

A new survey reveals that only 20% of Americans view covid-19 as "a major threat"…



Survey Shows Declining Concerns Among Americans About COVID-19

A new survey reveals that only 20% of Americans view covid-19 as "a major threat" to the health of the US population - a sharp decline from a high of 67% in July 2020.


What's more, the Pew Research Center survey conducted from Feb. 7 to Feb. 11 showed that just 10% of Americans are concerned that they will  catch the disease and require hospitalization.

"This data represents a low ebb of public concern about the virus that reached its height in the summer and fall of 2020, when as many as two-thirds of Americans viewed COVID-19 as a major threat to public health," reads the report, which was published March 7.

According to the survey, half of the participants understand the significance of researchers and healthcare providers in understanding and treating long COVID - however 27% of participants consider this issue less important, while 22% of Americans are unaware of long COVID.

What's more, while Democrats were far more worried than Republicans in the past, that gap has narrowed significantly.

"In the pandemic’s first year, Democrats were routinely about 40 points more likely than Republicans to view the coronavirus as a major threat to the health of the U.S. population. This gap has waned as overall levels of concern have fallen," reads the report.

More via the Epoch Times;

The survey found that three in ten Democrats under 50 have received an updated COVID-19 vaccine, compared with 66 percent of Democrats ages 65 and older.

Moreover, 66 percent of Democrats ages 65 and older have received the updated COVID-19 vaccine, while only 24 percent of Republicans ages 65 and older have done so.

“This 42-point partisan gap is much wider now than at other points since the start of the outbreak. For instance, in August 2021, 93 percent of older Democrats and 78 percent of older Republicans said they had received all the shots needed to be fully vaccinated (a 15-point gap),” it noted.

COVID-19 No Longer an Emergency

The U.S. Centers for Disease Control and Prevention (CDC) recently issued its updated recommendations for the virus, which no longer require people to stay home for five days after testing positive for COVID-19.

The updated guidance recommends that people who contracted a respiratory virus stay home, and they can resume normal activities when their symptoms improve overall and their fever subsides for 24 hours without medication.

“We still must use the commonsense solutions we know work to protect ourselves and others from serious illness from respiratory viruses, this includes vaccination, treatment, and staying home when we get sick,” CDC director Dr. Mandy Cohen said in a statement.

The CDC said that while the virus remains a threat, it is now less likely to cause severe illness because of widespread immunity and improved tools to prevent and treat the disease.

Importantly, states and countries that have already adjusted recommended isolation times have not seen increased hospitalizations or deaths related to COVID-19,” it stated.

The federal government suspended its free at-home COVID-19 test program on March 8, according to a website set up by the government, following a decrease in COVID-19-related hospitalizations.

According to the CDC, hospitalization rates for COVID-19 and influenza diseases remain “elevated” but are decreasing in some parts of the United States.

Tyler Durden Sun, 03/10/2024 - 22:45

Read More

Continue Reading


Rand Paul Teases Senate GOP Leader Run – Musk Says “I Would Support”

Rand Paul Teases Senate GOP Leader Run – Musk Says "I Would Support"

Republican Kentucky Senator Rand Paul on Friday hinted that he may jump…



Rand Paul Teases Senate GOP Leader Run - Musk Says "I Would Support"

Republican Kentucky Senator Rand Paul on Friday hinted that he may jump into the race to become the next Senate GOP leader, and Elon Musk was quick to support the idea. Republicans must find a successor for periodically malfunctioning Mitch McConnell, who recently announced he'll step down in November, though intending to keep his Senate seat until his term ends in January 2027, when he'd be within weeks of turning 86. 

So far, the announced field consists of two quintessential establishment types: John Cornyn of Texas and John Thune of South Dakota. While John Barrasso's name had been thrown around as one of "The Three Johns" considered top contenders, the Wyoming senator on Tuesday said he'll instead seek the number two slot as party whip. 

Paul used X to tease his potential bid for the position which -- if the GOP takes back the upper chamber in November -- could graduate from Minority Leader to Majority Leader. He started by telling his 5.1 million followers he'd had lots of people asking him about his interest in running...

...then followed up with a poll in which he predictably annihilated Cornyn and Thune, taking a 96% share as of Friday night, with the other two below 2% each. 

Elon Musk was quick to back the idea of Paul as GOP leader, while daring Cornyn and Thune to follow Paul's lead by throwing their names out for consideration by the Twitter-verse X-verse. 

Paul has been a stalwart opponent of security-state mass surveillance, foreign interventionism -- to include shoveling billions of dollars into the proxy war in Ukraine -- and out-of-control spending in general. He demonstrated the latter passion on the Senate floor this week as he ridiculed the latest kick-the-can spending package:   

In February, Paul used Senate rules to force his colleagues into a grueling Super Bowl weekend of votes, as he worked to derail a $95 billion foreign aid bill. "I think we should stay here as long as it takes,” said Paul. “If it takes a week or a month, I’ll force them to stay here to discuss why they think the border of Ukraine is more important than the US border.”

Don't expect a Majority Leader Paul to ditch the filibuster -- he's been a hardy user of the legislative delay tactic. In 2013, he spoke for 13 hours to fight the nomination of John Brennan as CIA director. In 2015, he orated for 10-and-a-half-hours to oppose extension of the Patriot Act

Rand Paul amid his 10 1/2 hour filibuster in 2015

Among the general public, Paul is probably best known as Capitol Hill's chief tormentor of Dr. Anthony Fauci, who was director of the National Institute of Allergy and Infectious Disease during the Covid-19 pandemic. Paul says the evidence indicates the virus emerged from China's Wuhan Institute of Virology. He's accused Fauci and other members of the US government public health apparatus of evading questions about their funding of the Chinese lab's "gain of function" research, which takes natural viruses and morphs them into something more dangerous. Paul has pointedly said that Fauci committed perjury in congressional hearings and that he belongs in jail "without question."   

Musk is neither the only nor the first noteworthy figure to back Paul for party leader. Just hours after McConnell announced his upcoming step-down from leadership, independent 2024 presidential candidate Robert F. Kennedy, Jr voiced his support: 

In a testament to the extent to which the establishment recoils at the libertarian-minded Paul, mainstream media outlets -- which have been quick to report on other developments in the majority leader race -- pretended not to notice that Paul had signaled his interest in the job. More than 24 hours after Paul's test-the-waters tweet-fest began, not a single major outlet had brought it to the attention of their audience. 

That may be his strongest endorsement yet. 

Tyler Durden Sun, 03/10/2024 - 20:25

Read More

Continue Reading